Skip to content

Stroke prophylaxis with Apixaban in Chronic Kidney Disease stage 5 patients with Atrial fibrillation (SACK)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-501600-10-00
Enrollment
1280
Registered
2022-11-28
Start date
2023-02-07
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation and Chronic Kidney Disease stage 5

Brief summary

Ischemic stroke and systemic embolism (composite)

Detailed description

Composite event of intracranial bleeding (including hemorrhagic stroke) and fatal bleeding, Hospitalization for myocardial infarction, cardiovascular intervention, or cardiovascular death (composite), All-cause death, All-cause stroke or systemic embolism, Major bleeding (as defined in the International Society on Thrombosis and Haemostasias (ISTH) consensus)

Interventions

DRUGApixaban Accord 2.5 mg film-coated tablets

Sponsors

Karolinska University Hospital, Medical University Of Silesia Katowice Poland
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Ischemic stroke and systemic embolism (composite)

Secondary

MeasureTime frame
Composite event of intracranial bleeding (including hemorrhagic stroke) and fatal bleeding, Hospitalization for myocardial infarction, cardiovascular intervention, or cardiovascular death (composite), All-cause death, All-cause stroke or systemic embolism, Major bleeding (as defined in the International Society on Thrombosis and Haemostasias (ISTH) consensus)

Countries

Finland, Iceland, Netherlands, Norway, Poland, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026